TrkB

TrkB (tropomyosin receptor kinase B) is a receptor protein embedded in the outer membrane of neurons. Its primary role is to receive the signal carried by BDNF — brain-derived neurotrophic factor — and translate it into instructions for the cell to survive, grow new connections, and reinforce existing ones.

The receptor belongs to the Trk family, a small group of proteins that link neurotrophins — growth-promoting molecules — to the cellular machinery that shapes neural architecture over time. TrkB is particularly dense in the hippocampus and prefrontal cortex, regions central to memory, learning, and emotional regulation, and is expressed broadly wherever long-term synaptic change matters.

How it works · its role

When BDNF binds to TrkB, two receptor molecules pair up and their intracellular kinase domains phosphorylate each other. That phosphorylation activates several downstream cascades — chiefly through the MAPK/ERK, PI3K/Akt, and PLCγ pathways — that instruct neurons to survive, extend dendritic spines, and strengthen synaptic connections. The overall effect is increased synaptic density and more adaptive circuitry.

A separate line of research suggests that certain psychedelic compounds — psilocin, LSD, and DMT among them — may bind TrkB directly, at a site distinct from where BDNF attaches. This would allow the receptor to be activated without any prior change in BDNF levels. The evidence is from cell cultures and animal models and has not been directly confirmed in human tissue.

Relevance to substances & effects

Ketamine is the most clinically studied substance in this context. It is thought to trigger a rapid surge of BDNF in the prefrontal cortex, which then activates TrkB and drives fast synaptogenesis — one proposed explanation for ketamine's unusually quick antidepressant effect, measured in hours rather than weeks. Classic antidepressants such as SSRIs also upregulate the BDNF–TrkB axis, but through slower upstream routes.

Serotonergic psychedelics are associated with what researchers call neuroplasticity — a heightened capacity for synaptic remodelling. The proposed direct TrkB binding is one candidate mechanism; activation of 5-HT₂A receptors, which also feeds back into BDNF signalling, is another. These routes are not mutually exclusive, and the lasting cognitive or perceptual changes sometimes reported after psychedelic use have been linked to TrkB-mediated structural shifts, though isolating this contribution from the broader pharmacology remains an open question.